{
    "clinical_study": {
        "@rank": "148173", 
        "arm_group": [
            {
                "arm_group_label": "HCap Formula", 
                "arm_group_type": "Experimental", 
                "description": "Pill of HCap Formula every other day for 6 month during the treatment phase; Follow up phase: nothing."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Same as treatment with placebo pills"
            }
        ], 
        "brief_summary": {
            "textblock": "HCap Formula is composed of medicinal plants, vitamins and minerals.  The purpose of this\n      study is to evaluate the efficacy of HCap Formula, a nutrition supplement for promoting hair\n      growth in men with tendencies for hair loss."
        }, 
        "brief_title": "Efficacy of Nutrition Supplement for Treatment of Men With Hair Loss", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Androgenetic Alopecia", 
        "condition_browse": {
            "mesh_term": [
                "Alopecia", 
                "Alopecia Areata"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study consists of a treatment phase (6 months) and a follow-up phase (6 month ).\n      Eligible subjects will be randomly assigned to receive treatment with the study medication\n      or placebo.  Subjects will visit the clinic at 3, 6, and 12 months after treatment start for\n      safety and efficacy evaluations.\n\n      HCap Formula or placebo tablets will be taken orally every other day during 6 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy males between 18-40 years of age.\n\n          2. No abnormality in blood tests analysis\n\n          3. Present with mild to moderate androgenic alopecia (AGA) graded IIv, IIIv, IV or V\n             according to the Hamilton-Norwood  classification\n\n          4. Willingness to use the same shampoo, refrain from change in hair style, and refrain\n             from hair dyeing during the study.\n\n          5. Willingness to refrain from any therapy affecting hair during the study\n\n          6. Willingness to have photographs of the treated area taken.\n\n          7. Willingness to follow the treatment schedule and post treatment follow-up.\n\n          8. Willingness not participate on other studies during the study course\n\n        Exclusion Criteria:\n\n        General\n\n          1. Having a known allergy to any of the ingredients in the test products;\n\n          2. Participation in a study of another device or drug within one month prior to\n             enrollment or during the study.\n\n             Hair treatments/ scalp condition\n\n          3. Undergone hair transplant surgery, scalp reduction surgery\n\n          4. Having hair weave or tattooing of the alopecic area.\n\n          5. Other hair loss disorders, such as alopecia areata, scarring alopecia.\n\n          6. Suffering from any active dermatological condition in the treated area such as scalp\n             atrophy, which in the opinion of the investigator might interfere with clinical\n             evaluation.\n\n             Medications\n\n             Use of the following medications within the past 6 months:\n\n          7. Prescription or over-the-counter systemic or topical treatment specific for\n             androgenic alopecia (such as minoxidil, finasteride, dutasteride).\n\n          8. 5\u03b1-reductase inhibitors for prostate conditions (e.g. benign prostate hyperplasia,\n             prostate cancer) and hormone replacement therapy for transgenders\n\n          9. Medications with anti-androgenic properties (cyproterone, spironolactone,\n             ketoconazole, flutamide, progesterone, and bicalutamide)\n\n         10. Medications that can potentially cause hypertrichosis (e.g. cyclosporine, diazoxide,\n             phenothiazines, zidovudine, tamoxifen, carpronium chloride),\n\n         11. Medications that can potentially cause alopecia such as oral glucocorticoids,\n             lithium, phenothiazines, tamoxifen.\n\n             Use of the following medications within the past 3 months:\n\n         12. Botanicals/nutraceuticals for hair growth\n\n         13. Steroids - systemic steroids for more than 14 days (e.g. corticosteroids, anabolic\n             steroids) or topical steroids on the area of hair loss.\n\n             Other medical conditions\n\n         14. Suffering from significant concurrent illness, such as cardiac disorders, diabetes\n             (type I or II), uncontrolled hypertension, symptomatic hypotension, hyper/hypo\n             thyroidism, or pertinent neurological disorders.\n\n         15. Suffering from serious medical condition that could adversely affect hair loss such\n             as immunosuppression/immune deficiency disorders (including HIV), history of cancer\n             or having/undergoing any form of treatment for active cancer, connective tissue\n             disorder, inflammatory bowel disease\n\n         16. As per the Investigator's discretion, any physical or mental condition which might\n             make it unsafe for the subject to participate in this study."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02150187", 
            "org_study_id": "ProHair01"
        }, 
        "intervention": [
            {
                "arm_group_label": "HCap Formula", 
                "description": "Pill should be taken every other day during the treatment phase.", 
                "intervention_name": "HCap Formula", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Similar pills without active ingredients", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Androgenetic Alopecia", 
            "Male", 
            "Baldness", 
            "hair loss pattern"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": {
            "contact": {
                "email": "ProHair01@gmail.com", 
                "last_name": "Lilach Gavish, PhD", 
                "phone": "97225635673"
            }, 
            "facility": {
                "address": {
                    "city": "Jerusalem", 
                    "country": "Israel", 
                    "zip": "9644035"
                }, 
                "name": "Dr David Friedman Laser & Skin Center"
            }, 
            "investigator": [
                {
                    "last_name": "David J Friedman, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Lilach Gavish, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Louis Weinrauch, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluation of the Efficacy of Hcap Formula Nutrition Supplement for Treatment of Men With Androgenic Alopecia: A Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial", 
        "overall_contact": {
            "email": "ProHair01@gmail.com", 
            "last_name": "Lilach Gavish, PhD", 
            "phone": "97225635673"
        }, 
        "overall_official": [
            {
                "affiliation": "Friedman Skin & Laser Center", 
                "last_name": "David J Friedman, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Friedman Skin & Laser Center", 
                "last_name": "Lilach Gavish, PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Israeli Health Ministry Pharmaceutical Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome will be change in the terminal hair count from baseline to 26 Weeks within a 3 cm diameter circle based on macro-photographs of the same area.  The treatment group will be compared to the control.", 
            "measure": "Changes in Terminal Hair Count at 26 Weeks Compared to Baseline", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 26 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02150187"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Assessment of improvement using a 7-point scale: greatly decreased (-3), moderately decreased (-2), slightly decreased (-1), no change (0), slightly increased (1), moderately increased (2), and greatly increased (3). This assessment will be performed by comparing the global photographs obtained at Baseline with those subsequently obtained at baseline, 26, and 52 weeks. This assessment will be carried out separately on the global photography of the vertex and frontal views", 
            "measure": "Global Assessment of Improvement from Baseline to 26 and 52 weeks Assessed for Vertex and Frontal Views Separately", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 26 weeks, 52 weeks"
        }, 
        "source": "Family Marketing", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Family Marketing", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}